ArgenX highlights new Vyvgart data, demonstrating early disease control in ocular MG
On 26 February, ArgenX announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the Phase III Adapt …
Post
-
-
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Theravance Biopharma is restructuring its R&D organisation and cutting its workforce by approximately half after its rare disease blood pressure …
-
Syntis Bio begins patient dosing in Phase I trial of SYNT-101 for obesity
Syntis Bio has dosed the first patient in the SYNTIETY-1 Phase I/Ib trial of SYNT-101, its investigational once-daily oral pill, …
-
Kyowa Kirin discontinues ongoing trials of rocatinlimab
Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody under investigation …
-
Extracellular vesicles: The next frontier in regenerative medicine and drug delivery?
Extracellular vesicles (EVs) are tiny, membrane-bound particles released by every cell type studied to date. Though small, they carry a …
-
Faron and City of Hope to develop Phase II trial of bexmarilimab for r/r MDS
Faron Pharmaceuticals has collaborated with cancer research organisation City of Hope to develop a Phase II investigator-initiated trial for evaluating …
-
FDA releases hold on second of Intellia’s ATTR-CM gene therapy trials
The US Food and Drug Administration (FDA) has released the clinical hold on a second trial evaluating Intellia Therapeutics’ transthyretin …
-
Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, …
-
Dermatology Trials by the Numbers: Key Trends and Benchmarks for 2026
Dermatology - spanning chronic inflammatory disease, infection, wound healing, pigment disorders, hair loss and rare genetic conditions - is nothing …
-
FDA tells uniQure to conduct another study of Huntington’s gene therapy
uniQure's stock has dropped by more than 40% after being asked to conduct another study of its Huntington’s disease gene …
-
BlueWind’s Revi urinary incontinence device demonstrates three-year efficacy
BlueWind Medical’s Revi implantable tibial neuromodulation (ITNM) system has demonstrated sustained efficacy and safety at the three-year mark in a …
-
MSD announces results from Keytruda combination trial for RCC
Merck (MSD) has announced findings from the pivotal Phase III LITESPARK-022 trial, assessing the combination of Keytruda (pembrolizumab) and Welireg …
-
Opus Genetics reports Phase I/II trial results of OPGx-BEST1 gene therapy
Opus Genetics has reported early findings from its ongoing Phase I/II clinical trial of the OPGx-BEST1 gene therapy for the …
-
OCT West Coast: China’s clinical trial infrastructure delivers upto 60% cost savings
China’s rise as a source of innovative drugs is being driven by clinical trial environment that is proving to be …
-
Rare Disease Day: Revolutionising clinical trial enrolment and retention with technology
As we mark Rare Disease Day 2026, it is worth reflecting on the developments in digitalisation, artificial intelligence (AI), and …
